FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs
For women with HER2-positive early breast cancer, concurrent therapy with ACE inhibitor lisinopril can help to prevent a decline in left-ventricular ejection fraction (LVEF).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2021 Category: Cancer & Oncology Tags: Cardiology News Source Type: news
' Smart Bomb' Salvage in HER+ Metastatic CRC'Smart Bomb' Salvage in HER+ Metastatic CRC
The higher the HER2 expression, the more benefit patients get from the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mCRC in the salvage setting, according to a phase 2 report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ASCO: Adding Olaparib Slows High - Risk Early Breast Cancer
Higher rates of invasive disease - free survival seen in adjuvant setting for HER2 - negative early - stage disease with germline BRCA1 or BRCA2 mutations (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
IL-6 Levels Predict Distant Breast Cancer Recurrence IL-6 Levels Predict Distant Breast Cancer Recurrence
Interleukin 6 may be a biomarker for distant recurrence of breast cancer among patients treated for stage II-III HER2-negative disease, investigators have found. The evidence was presented at ASCO 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ASCO: Adding Olaparib Slows High-Risk Early Breast Cancer
FRIDAY, June 4, 2021 -- The addition of therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in an adjuvant setting improves invasive disease-free survival in early-stage human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news
Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer
Basel, 4 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the presentation of new and updated data on giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in people with hormone receptor (HR)-positive, HER2-negative breast cancer. Breast cancer is now the most common cancer in the world, with HR-positive being the most common subtype representing 70% of cases.1,2 Data from these studies will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.“We’re encouraged by ...
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news
ECOG-ACRIN research highlights at ASCO 2021
(ECOG-ACRIN Cancer Research Group) Platinum chemotherapy fails for triple-negative breast cancer, basal-like subtype. The first racially diverse trial to look at severe joint pain from aromatase inhibitors shows more postmenopausal Black and Asian women with early breast cancer developed this common/significant syndrome. Less intense therapy for HPV-associated throat cancer shows outstanding three-year survival and quality of life. Inflammation biomarker links to distant recurrence of HER2-negative early breast cancer. Joseph A. Sparano receives ASCO's 2021 Gianni Bonadonna Breast Cancer Award and Lecture. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2021 Category: Cancer & Oncology Source Type: news
Evolving Strategies in Sequencing for HER2+ MBC Therapy Evolving Strategies in Sequencing for HER2+ MBC Therapy
Therapies targeting HER2+ MBC are evolving rapidly. Several recent FDA approvals offer experts an array of new options and prompt a reevaluation of treatments and sequencing strategies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
(University of Texas M. D. Anderson Cancer Center) Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that ...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Tumor marker may help overcome endocrine treatment-resistant breast cancer
(Sanford Burnham Prebys Medical Discovery Institute) A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news
A path to aggressive breast cancer
(Baylor College of Medicine) Following the progression of breast cancer in an animal model revealed a path that transforms a slow-growing cancer type known as estrogen receptor (ER)+/HER2+ into a fast-growing ER-/HER2+ type that aggressively spreads or metastasizes to other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news
BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Study finds mechanism leading to herceptin resistance and Rx approach to reverse it
(Louisiana State University Health Sciences Center) Research conducted by an international team of scientists discovered a mechanism that leads to Herceptin resistance, representing a significant clinical obstacle to successfully treating HER2-positive breast cancer. They also identified a new approach to potentially overcome it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news
